A GlaxoSmithKline logo is seen outside one of its buildings in west London in this February 6, 2008 file photograph. GlaxoSmithKline Plc has agreed to plead guilty to criminal charges and pay $3 billion to settle the largest case of healthcare fraud in ...
LONDON/BOSTON GlaxoSmithKline Plc is to acquire its long-time partner Human Genome Sciences Inc for a sweetened offer of about $3 billion, ending on friendly terms a three-month hostile pursuit of the U.S.
After spurning a hostile takeover bid from GlaxoSmithKline PLC in April, Human Genome Sciences Inc. said Monday it agreed to be bought by the biopharmaceutical giant for a more lucrative offer valued at $3.6 billion.
GlaxoSmithKline PLC's $3 billion criminal and civil settlement with the U.S. government this week raises questions about the future of asthma treatment Advair—the company's biggest moneymaker and one of the top-selling drugs in the world.
“If you look at Euro-related equities, in terms of their valuation, over the top of U.S. valuations, that disparity is at a 40-year low,” says Mark Luschini, chief investment strategist at Janney Montgomery.
On July 16, 2012, Reuters reported that Glaxosmithkline Plc is expected to announce an agreement to acquire Human Genome Sciences Inc for about $2.8 billion as soon as Monday, ending three months of its hostile pursuit of the U.S.